Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Lara PN Jr, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. Lara PN Jr, et al. Among authors: ramalingam s. Clin Lung Cancer. 2011 Jan;12(1):33-7. doi: 10.3816/CLC.2011.n.004. Clin Lung Cancer. 2011. PMID: 21273177 Free PMC article. Clinical Trial.
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR. Gitlitz BJ, et al. Among authors: ramalingam s. J Thorac Oncol. 2012 Mar;7(3):574-8. doi: 10.1097/JTO.0b013e31823f43ca. J Thorac Oncol. 2012. PMID: 22198425 Free PMC article. Clinical Trial.
Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ. Belani CP, et al. Among authors: ramalingam s. J Clin Oncol. 2008 Jan 20;26(3):468-73. doi: 10.1200/JCO.2007.13.1912. J Clin Oncol. 2008. PMID: 18202422 Clinical Trial.
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S, Forster J, Naret C, Evans T, Sulecki M, Lu H, Teegarden P, Weber MR, Belani CP. Ramalingam S, et al. J Thorac Oncol. 2008 Mar;3(3):258-64. doi: 10.1097/JTO.0b013e3181653d1b. J Thorac Oncol. 2008. PMID: 18317068 Free article. Clinical Trial.
1,134 results